TrialAmerican journal of ophthalmology2022

Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5.

Maria A Parker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.